The primary objective of this proposal is to examine the receptor tyrosine kinase AXL as a driver of cetuximab resistance in Head and Neck Cancer (HNC). Cetuximab, a monoclonal antibody targeting the EGFR, is the only approved molecular targeting agent in the management of HNC. Despite well established benefit, the majority of patients do not respond to cetuximab, and those who do respond ultimately manifest resistance. Intrinsic and acquired resistance to cetuximab is a major obstacle to improving treatment outcome in HNSCC. Further, limited molecular understanding of cetuximab resistance mechanisms reveals a gap in knowledge in HNC therapy. To identify novel, targetable mechanisms of cetuximab resistance in HNC we employ human tumors, patient-derived xenografts (PDXs), and several models of intrinsic and acquired resistance. We have identified that 1) AXL is overexpressed in HNC and is significantly associated with higher pathologic grade, metastases, and shorter survival, 2) PDXs resistant to cetuximab have high AXL expression compared to cetuximab-sensitive PDXs, and AXL blockade can re-sensitize resistant tumors, 3) overexpression of AXL in cetuximab-sensitive HNC lines render them resistant, whereas kinase dead AXL lines retain sensitivity, 4) therapeutic targeting of AXL can restore sensitivity to cetuximab in the resistant setting and 5) a unique mechanism of resistance is identified where AXL activates Src Family Kinases (SFKs) leading to sustained HER3 signaling. In this proposal we hypothesize that AXL plays an important role in HNC pathogenesis and therapeutic resistance to cetuximab and that AXL mediates resistance by activating the HER3/PI3K/Akt axis via SFKs. To test this hypothesis, we will determine 1) if AXL mediates cetuximab resistance in HNC via a unique circuit involving the SFKs and HER3 (2) If targeting AXL in cetuximab-resistant HNC tumors can increase the efficacy of cetuximab in HNC (3) if AXL serves as a biomarker for cetuximab-resistance in HNC and 4) if cetuximab-resistant tumors, taken directly from patients, can be sensitized to cetuximab by inhibiting AXL signaling. To carry out these studies we have assembled a strong team of molecular biologists, translational physician-scientists, pathologists and biostatisticians. This investigative strategy holds great promise for translation to the clinic and brings innovation by leveraging new molecular insights to a significant existing problem in HNC.
The only approved molecular targeting agent in the treatment of HNC is cetuximab, an antibody directed against the EGFR. The vast majority of patients are either intrinsically resistant or acquire resistance to this promising agent. We have identified the receptor tyrosine kinase AXL as a major driver of cetuximab resistance. We will investigate how AXL mediates resistance, whether AXL blockade can re-sensitize resistant tumors and if AXL can serve as a biomarker to predict cetuximab resistance in HNC.
| McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308 |
| Blitzer, Grace C; Rosenberg, Stephen A; Anderson, Bethany M et al. (2018) Results From 10 Years of a Free Oral Cancer Screening Clinic at a Major Academic Health Center. Int J Radiat Oncol Biol Phys 102:146-148 |
| Burr, Adam R; Harari, Paul M; Ko, Huaising C et al. (2018) HPV impacts survival of stage IVC non-oropharyngeal HNSCC cancer patients. Otorhinolaryngol Head Neck Surg 3: |
| Elsaid, Mohamed Y; Shahi, Ankita; Wang, Albert R et al. (2018) Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog. Mol Cancer Ther 17:2320-2328 |
| Jeong, Woo-Jin; Bu, Jiyoon; Kubiatowicz, Luke J et al. (2018) Peptide-nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms? Nano Converg 5:38 |
| Nyman, Patrick E; Buehler, Darya; Lambert, Paul F (2018) Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis. Clin Cancer Res 24:6308-6318 |
| Ko, Huaising C; Chen, Shuai; Wieland, Aaron M et al. (2017) Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database. Head Neck 39:2159-2170 |
| Werner, Lauryn R; Kler, Jasdeep S; Gressett, Monica M et al. (2017) Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma. Radiother Oncol 124:418-426 |
| Prabakaran, Prashanth J; Javaid, Amal M; Swick, Adam D et al. (2017) Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition. Clin Cancer Res 23:6044-6053 |
| Ko, Huaising C; Harari, Paul M; Chen, Shuai et al. (2017) Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx. JAMA Otolaryngol Head Neck Surg 143:1126-1133 |
Showing the most recent 10 out of 12 publications
